New drug cocktail aims to stop deadly transplant complication
NCT ID NCT07249346
First seen Jan 08, 2026 · Last updated Jun 23, 2026 · Updated 26 times
Summary
This phase 2 trial tests whether adding ruxolitinib to standard drugs (cyclophosphamide and tacrolimus) can prevent severe graft-versus-host disease (GVHD) in 124 adults with blood cancers like leukemia. Participants receive a stem cell transplant after high-dose chemotherapy, then the drug combo. The main goal is to see if more patients survive without severe GVHD at 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ruxolitinib, cyclophosphamide, tacrolimus
What this could lead to
If successful, this could offer a safer way to prevent severe graft-versus-host disease after stem cell transplants, improving survival and quality of life for blood cancer patients.
What could go wrong
This is an early phase 2 trial with only 124 participants, so results may not apply to everyone. The drug combination may still cause serious side effects or fail to prevent GVHD.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.